Literature DB >> 22460147

Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?

Désirée van der Heijde1.   

Abstract

Remission is often selected as the 'treat to target'. There is a plea to include imaging. Imaging remission can apply to structural damage and/or inflammation. For structural damage, radiographs are mostly used. A definition is needed which could be either strict, with no progression occurring, or which takes measurement error into account and uses the smallest detectable change. Mostly imaging remission refers to inflammation as assessed by ultrasound or MRI. The reason for arguing that imaging remission should be included for inflammation is that inflammation may still be present in patients who are in clinical remission. The level of inflammation depends on the clinical remission definition that is used. Bone marrow oedema is the feature that is most predictive of radiographic progression. However, before imaging remission can be implemented as a recommendation, a definition of remission by imaging needs to be established. A choice has to be made about the level of inflammation that can be tolerated and how this needs to be assessed (which imaging method, which feature, which joints, which cut-off point). Moreover, imaging remission should only be selected as a target if it can be proved that it can be treated and that the outcome of the patients will be improved by trying to achieve imaging remission in addition to clinical remission. This proof is not yet available, and too many unanswered questions remain to recommend including imaging remission of inflammation in a definition of remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460147     DOI: 10.1136/annrheumdis-2011-200797

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

Review 1.  Insights into rheumatoid arthritis from use of MRI.

Authors:  Fiona M McQueen; Estee Chan
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

2.  A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis.

Authors:  Eugenio de Miguel; Angela Pecondón-Español; Manuel Castaño-Sánchez; Alfonso Corrales; Ricardo Gutierrez-Polo; Manuel Rodriguez-Gomez; Jose A Pinto-Tasende; Jose L Rivas; José Ivorra-Cortés
Journal:  Rheumatol Int       Date:  2017-04-07       Impact factor: 2.631

3.  Treat-to-target strategies aiming at additional ultrasound remission is associated with better control of disease activity and less flare in rheumatoid arthritis.

Authors:  Yan Geng; Liujun Wang; Xiaohui Zhang; Lanlan Ji; Xuerong Deng; Zhuoli Zhang
Journal:  Clin Rheumatol       Date:  2020-06-08       Impact factor: 2.980

4.  Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial.

Authors:  Espen A Haavardsholm; Anna-Birgitte Aga; Inge Christoffer Olsen; Siri Lillegraven; Hilde B Hammer; Till Uhlig; Hallvard Fremstad; Tor Magne Madland; Åse Stavland Lexberg; Hilde Haukeland; Erik Rødevand; Christian Høili; Hilde Stray; Anne Noraas; Inger Johanne Widding Hansen; Gunnstein Bakland; Lena Bugge Nordberg; Désirée van der Heijde; Tore K Kvien
Journal:  BMJ       Date:  2016-08-16

Review 5.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

6.  Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Authors:  Karina I Halilova; Elizabeth E Brown; Sarah L Morgan; S Louis Bridges; Min-Ho Hwang; Donna K Arnett; Maria I Danila
Journal:  Int J Rheumatol       Date:  2012-07-09

7.  Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Authors:  Emese Balogh; Joao Madruga Dias; Carl Orr; Ronan Mullan; Len Harty; Oliver FitzGerald; Phil Gallagher; Miriam Molloy; Eileen O'Flynn; Alexia Kelly; Patricia Minnock; Madeline O'Neill; Louise Moore; Mairead Murray; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2013-12-24       Impact factor: 5.156

8.  Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis.

Authors:  M Gärtner; I K Sigmund; F Alasti; G Supp; H Radner; K Machold; J S Smolen; D Aletaha
Journal:  RMD Open       Date:  2016-04-07

9.  Patient's perspective of sustained remission in rheumatoid arthritis.

Authors:  Irazú Contreras-Yáñez; Guillermo Guaracha-Basañez; Daniel Ruiz-Domínguez; Virginia Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2017-09-02       Impact factor: 2.362

10.  The added value of musculoskeletal ultrasound to clinical evaluation in the treatment decision of rheumatoid arthritis outpatients: physician experience matters.

Authors:  C Sifuentes-Cantú; I Contreras-Yáñez; L Saldarriaga; A C Lozada; M Gutiérrez; V Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2017-09-11       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.